Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Diagnosis & Disease Information
Eponyms in Oncology: Waldenström Macroglobulinemia
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Ibrutinib Improves Long-Term Outcomes in Waldenstrom’s Macroglobulinemia
Adding ibrutinib to rituximab improved responses and progression-free survival.
Triplet Deemed ‘Patient-Friendly’ for Relapsed/Refractory Waldenstrom Macroglobulinemia
Responses improved over time, and the best overall response rate was 85%.
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Partial Response or Better Associated With Prolonged PFS With Ibrutinib in WM
Response depth appeared to be predictive of PFS in WM patients treated with ibrutinib.
Case Report Details COVID-19 Reinfection in Immunocompromised Patient
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Ibrutinib Effectiveness in Symptomatic, Previously Treated Waldenström Macroglobulinemia
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...